vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $124.5M, roughly 1.5× PagerDuty, Inc.). PagerDuty, Inc. runs the higher net margin — 129.7% vs -0.7%, a 130.5% gap on every dollar of revenue. On growth, PagerDuty, Inc. posted the faster year-over-year revenue change (4.7% vs 0.7%). PagerDuty, Inc. produced more free cash flow last quarter ($24.1M vs $21.3M). Over the past eight quarters, PagerDuty, Inc.'s revenue compounded faster (5.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
AVNS vs PD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $124.5M |
| Net Profit | $-1.3M | $161.6M |
| Gross Margin | 47.5% | 85.3% |
| Operating Margin | 1.4% | 6.5% |
| Net Margin | -0.7% | 129.7% |
| Revenue YoY | 0.7% | 4.7% |
| Net Profit YoY | 99.7% | 2827.7% |
| EPS (diluted) | $-0.02 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $124.5M | ||
| Q3 25 | $177.8M | $123.4M | ||
| Q2 25 | $175.0M | $119.8M | ||
| Q1 25 | $167.5M | $121.4M | ||
| Q4 24 | $179.6M | $118.9M | ||
| Q3 24 | $170.4M | $115.9M | ||
| Q2 24 | $171.7M | $111.2M | ||
| Q1 24 | $166.1M | $111.1M |
| Q4 25 | $-1.3M | $161.6M | ||
| Q3 25 | $-1.4M | $9.6M | ||
| Q2 25 | $-76.8M | $-7.2M | ||
| Q1 25 | $6.6M | $-8.8M | ||
| Q4 24 | $-397.3M | $-5.9M | ||
| Q3 24 | $4.3M | $-10.9M | ||
| Q2 24 | $1.8M | $-17.1M | ||
| Q1 24 | $-900.0K | $-28.2M |
| Q4 25 | 47.5% | 85.3% | ||
| Q3 25 | 48.4% | 84.6% | ||
| Q2 25 | 52.6% | 84.0% | ||
| Q1 25 | 53.6% | 83.6% | ||
| Q4 24 | 54.6% | 83.0% | ||
| Q3 24 | 54.5% | 82.7% | ||
| Q2 24 | 55.7% | 82.6% | ||
| Q1 24 | 57.1% | 81.7% |
| Q4 25 | 1.4% | 6.5% | ||
| Q3 25 | 0.1% | 2.9% | ||
| Q2 25 | -42.6% | -8.6% | ||
| Q1 25 | 6.1% | -9.6% | ||
| Q4 24 | -233.0% | -8.7% | ||
| Q3 24 | 7.0% | -13.8% | ||
| Q2 24 | 3.7% | -19.5% | ||
| Q1 24 | 2.4% | -30.1% |
| Q4 25 | -0.7% | 129.7% | ||
| Q3 25 | -0.8% | 7.8% | ||
| Q2 25 | -43.9% | -6.0% | ||
| Q1 25 | 3.9% | -7.2% | ||
| Q4 24 | -221.2% | -5.0% | ||
| Q3 24 | 2.5% | -9.4% | ||
| Q2 24 | 1.0% | -15.4% | ||
| Q1 24 | -0.5% | -25.3% |
| Q4 25 | $-0.02 | $1.69 | ||
| Q3 25 | $-0.03 | $0.10 | ||
| Q2 25 | $-1.66 | $-0.07 | ||
| Q1 25 | $0.14 | $-0.12 | ||
| Q4 24 | $-8.64 | $-0.07 | ||
| Q3 24 | $0.09 | $-0.14 | ||
| Q2 24 | $0.04 | $-0.26 | ||
| Q1 24 | $-0.02 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $547.8M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $320.5M |
| Total Assets | $1.1B | $1.0B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $547.8M | ||
| Q3 25 | $70.5M | $567.9M | ||
| Q2 25 | $90.3M | $597.1M | ||
| Q1 25 | $97.0M | $570.8M | ||
| Q4 24 | $107.7M | $542.2M | ||
| Q3 24 | $89.0M | $599.3M | ||
| Q2 24 | $92.2M | $592.8M | ||
| Q1 24 | $75.8M | $571.2M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | $484.5M | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | $489.5M |
| Q4 25 | $778.2M | $320.5M | ||
| Q3 25 | $778.0M | $180.7M | ||
| Q2 25 | $776.3M | $145.7M | ||
| Q1 25 | $839.4M | $129.8M | ||
| Q4 24 | $828.5M | $111.6M | ||
| Q3 24 | $1.2B | $164.7M | ||
| Q2 24 | $1.2B | $174.0M | ||
| Q1 24 | $1.2B | $171.6M |
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.1B | $891.5M | ||
| Q2 25 | $1.0B | $926.8M | ||
| Q1 25 | $1.1B | $927.3M | ||
| Q4 24 | $1.2B | $866.8M | ||
| Q3 24 | $1.7B | $916.0M | ||
| Q2 24 | $1.7B | $924.0M | ||
| Q1 24 | $1.7B | $925.3M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | 3.73× | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $24.8M |
| Free Cash FlowOCF − Capex | $21.3M | $24.1M |
| FCF MarginFCF / Revenue | 11.8% | 19.3% |
| Capex IntensityCapex / Revenue | 3.8% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $24.8M | ||
| Q3 25 | $14.0M | $34.0M | ||
| Q2 25 | $6.8M | $30.7M | ||
| Q1 25 | $25.7M | $31.4M | ||
| Q4 24 | $57.9M | $22.1M | ||
| Q3 24 | $23.0M | $35.8M | ||
| Q2 24 | $27.8M | $28.6M | ||
| Q1 24 | $-8.0M | $22.2M |
| Q4 25 | $21.3M | $24.1M | ||
| Q3 25 | $7.0M | $33.1M | ||
| Q2 25 | $-4.2M | $30.2M | ||
| Q1 25 | $19.0M | $30.3M | ||
| Q4 24 | $53.1M | $21.5M | ||
| Q3 24 | $20.0M | $35.1M | ||
| Q2 24 | $21.9M | $28.2M | ||
| Q1 24 | $-12.1M | $21.2M |
| Q4 25 | 11.8% | 19.3% | ||
| Q3 25 | 3.9% | 26.8% | ||
| Q2 25 | -2.4% | 25.2% | ||
| Q1 25 | 11.3% | 24.9% | ||
| Q4 24 | 29.6% | 18.1% | ||
| Q3 24 | 11.7% | 30.3% | ||
| Q2 24 | 12.8% | 25.4% | ||
| Q1 24 | -7.3% | 19.1% |
| Q4 25 | 3.8% | 0.6% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 6.3% | 0.4% | ||
| Q1 25 | 4.0% | 0.9% | ||
| Q4 24 | 2.7% | 0.5% | ||
| Q3 24 | 1.8% | 0.5% | ||
| Q2 24 | 3.4% | 0.4% | ||
| Q1 24 | 2.5% | 0.9% |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 3.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
